MILANO – The take-off of Ita, made official by the agreement between the EU and the Italian government, also shakes the top of Recordati in a chain. The Milanese pharmaceutical company will in fact see the president Alfredo Altavilla leave, who resigned from 1 December 2021 precisely to go and become the executive president of Italy air transport. The current CEO, Andrea Recordati, will therefore take over the presidency of Recordati. While the new CEO, again from 1 December 2021, of the pharmaceutical group will be Rob Koremans.
Koremans, a medical graduate from the Rsm Erasmus University in the Netherlands, has over 30 years of experience in managerial and executive roles – explains the note that made the appointment official before the opening of the markets – matured mainly in the pharmaceutical industry at various companies international, including Serono, Grunenthal, Sanofi-Aventis and Teva.
He has worked all over the world and has lived in the Czech Republic, Germany, Switzerland and the Netherlands. In 2018 he was appointed chief executive officer of Nutreco, a leading global animal nutrition company. Previously, he was president and CEO of Global Specialty Medicines and a member of the executive committee of Teva pharmaceutical industries ltd.
Under the leadership of Rob Koremans, Recordati – whose majority passed from the family of the same name to the CVC fund in 2018 – will continue to “consolidate its trajectory, as defined in the recent three-year plan, combining organic growth with volumes of the current portfolio to value creation through Business Development and M&A operations “, explains the company. As future Chairman Andrea Recordati will continue to participate in the development of the Group’s strategy, in support of the new CEO and senior management team.
“I am very pleased that Rob is joining Recordati”, says Andrea Recordati after the decisions of the board of directors. “He is a manager – he adds – of great international experience with a solid track record in terms of growth and achievement of results, in the pharmaceutical and biotech sector. I will move to the role of President, ensuring continuity and I will work closely with Rob to support a transition. gradual and implementation of the business strategy “.
Koremans, for his part, said he was “thrilled to join Recordati and continue to guide it towards sustainable growth, helping people with a variety of diseases to face the health challenges they are experiencing. Recordati has a history full of successes. Under Andrea’s leadership, the company has continued to achieve excellent results. My commitment will be to pursue all opportunities for patients and all stakeholders, in order to continue Recordati’s success. ” Alfredo Altavilla is satisfied for having successfully contributed to Recordati’s evolution towards an institutional governance model, as agreed with the controlling shareholder at the time of my appointment as Chairman. This objective has been achieved, and given the new professional commitments undertaken recently , the time has come to leave the office of President “.
.